- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06534437
재발성 또는 불응성 공격성 B세포 비호지킨 림프종(JASPIS-01)을 치료하는 MEN1703(SEL24) (JASPIS-01)
재발성 또는 불응성 공격성 B세포 비호지킨 림프종 환자를 대상으로 MEN1703을 단독요법 및 글로피타맙과 병용하여 사용하는 오픈 라벨 제2상 임상 시험
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. The study will be open to groups at the same time:
- Group 1 - patients who have not had anti-CD3xCD20 bispecific antibody therapy but who have had at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma
- Group 2 - patients who have exhausted all standard treatment options including at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma Group 1 patients will be treated for a maximum of 12 cycles. One cycle is 21 days. Group 2 with be treated until the disease progresses, therefore treatment duration is dependent on the number of treatment cycles a participant receives prior to progression.
연구 개요
상세 설명
The study consists of 3 parts, to investigate MEN1703 (Dapolsertib hydrochloride) in combination with glofitamab in patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) or MEN1703 alone in patients who have exhausted all standard treatment options (group 2).
Part 1 (safety run-in) and Part 2 (enrichment): patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will receive either 150 mg or 125 mg of MEN1703 along with glofitamab. Patients who have exhausted all standard treatment options (group 2) will receive 125 mg of MEN1703 as a single-agent.
Part 3 (optional randomized comparison): Patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody therapy will be randomized to receive either MEN1703 (Dapolsertib hydrochloride) at a dose selected from part 2 in combination with glofitamab or glofitamab alone.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Head of Clinical Operations
- 전화번호: +48 123140200
- 이메일: clinicaltrials@ryvu.com
연구 장소
-
-
-
Barcelona, 스페인, 08035
- 모병
- Hospital Universitari Vall D Hebron
-
수석 연구원:
- Crisitna Garcia Herce, MD PhD
-
Madrid, 스페인, 28033
- 모병
- MD Anderson Cancer Center
-
수석 연구원:
- Adolfo De La Fuente Burguera, MD PhD
-
Madrid, 스페인
- 모병
- Hospital Universitario Puerta de Hierro Majadahonda
-
수석 연구원:
- Mariano Provencio Pulla, MD PhD
-
Madrid, 스페인, 28027
- 모병
- Clinica Universidad De Navarra
-
수석 연구원:
- Miguel Angel Canales Albendea, MD PhD
-
Murcia, 스페인, 30120
- 아직 모집하지 않음
- Hospital Clínico Uni versitario Virgen de la Arrixaca
-
수석 연구원:
- Ignacio Espanol Morales, Dr
-
Pamplona, 스페인, 31008
- 모병
- Clinica Universidad De Navarra
-
수석 연구원:
- Miguel Angel Canales Albendea, MD PhD
-
Pamplona, 스페인, 31008
- 모병
- Hospital Universitario De Navarra
-
수석 연구원:
- Jose Maria Arguinano Perez, MD PhD
-
Salamanca, 스페인, 37007
- 모병
- Hospital Universitario De Salamanca
-
수석 연구원:
- Norma Carmen Gutierrez, Prof.
-
Seville, 스페인, 41009
- 모병
- Hospital Universitario Virgen De La Macarena
-
수석 연구원:
- Natalia Palazon, MD PhD
-
Zaragoza, 스페인
- 모병
- Hospital Universitario Miguel Servet
-
수석 연구원:
- Araceli Rubio Martinez, MD PhD
-
-
-
-
-
Glasgow, 영국
- 모병
- Beatson West of Scotland Cancer Centre
-
수석 연구원:
- Mark Rafferty, Dr
-
Manchester, 영국
- 모병
- The Christie NHS Foundation Trust
-
수석 연구원:
- Kim Linton, Dr
-
Plymouth, 영국
- 모병
- Plymouth Hospitals NHS Trust
-
수석 연구원:
- David Burns, Dr
-
Sutton, 영국
- 모병
- The Royal Marsden Hospital
-
수석 연구원:
- David Cunningham, Dr
-
Tooting, 영국
- 모병
- St George's Hospital
-
수석 연구원:
- Ruth Pettengell, Dr
-
-
-
-
-
Biała Podlaska, 폴란드
- 종료됨
- Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
-
Bydgoszcz, 폴란드
- 모병
- IN-VIVO Bydgoszcz Sp. z o.o.
-
수석 연구원:
- Jarosław Czyż, Prof.
-
Gdansk, 폴란드
- 아직 모집하지 않음
- Klinika Hematologii I Transplantologii Uck
-
수석 연구원:
- Jan Zaucha, Prof.
-
Gdynia, 폴란드
- 모병
- Szpitale Pomorskie Sp. z o.o.
-
수석 연구원:
- Adam Witkowski, MD PhD
-
Gliwice, 폴란드
- 모병
- Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy
-
연락하다:
- Małgorzata Krawczyk-Kuliś, Prof.
-
수석 연구원:
- Małgorzata Krawczyk-Kuliś, Prof.
-
Katowice, 폴란드
- 종료됨
- Pratia Hematologia Sp. z o.o.
-
Krakow, 폴란드
- 모병
- SP ZOZ Szpital Uniwersytecki w Krakowie
-
수석 연구원:
- Agnieszka Giza, MD PhD
-
Krakow, 폴란드
- 모병
- Pratia MCM Kraków
-
연락하다:
- Wojciech Jurczak, Prof.
-
수석 연구원:
- Wojciech Jurczak, Prof.
-
Olsztyn, 폴란드
- 모병
- Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie
-
연락하다:
- Janusz Hałka, MD PhD
-
수석 연구원:
- Janusz Hałka, MD PhD
-
Skórzewo, 폴란드
- 모병
- Aidport Sp. z o.o.
-
수석 연구원:
- Michał Kwiatek, Dr
-
Torun, 폴란드
- 모병
- Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu
-
연락하다:
- Dominik Chraniuk, MD
-
수석 연구원:
- Dominik Chraniuk, MD
-
Warsaw, 폴란드
- 종료됨
- Lux Med Onkologia Sp. z o.o.
-
Warsaw, 폴란드
- 종료됨
- Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy
-
-
-
-
-
Le Mans, 프랑스, 72037
- 모병
- Centre Hospitalier Le Mans
-
수석 연구원:
- Kamel Laribi, MD PhD
-
Lille, 프랑스
- 모병
- CHU de Lille - Hôpital Claude Huriez
-
수석 연구원:
- Franck Morschhauser, Prof.
-
Limoges, 프랑스, 87042
- 모병
- CHU de Limoges - CHU Dupuytren
-
수석 연구원:
- Julie Abraham, MD PhD
-
Lyon, 프랑스, 69310
- 모병
- Hospices Civils De Lyon - Hôpital Lyon Sud
-
수석 연구원:
- Herve Ghesquieres, Prof.
-
Montpellier, 프랑스, 34490
- 모병
- CHU Montpellier - Hôpital Saint Eloi
-
수석 연구원:
- Guillaume Cartron, MD PhD
-
Paris, 프랑스, 75651
- 모병
- APHP - Hôpital Pitié-Salpêtrière
-
수석 연구원:
- Sylvain Choquet, MD PhD
-
Pessac, 프랑스, 33600
- 모병
- CHU de Bordeaux - Hôpital Haut-Lévêque
-
수석 연구원:
- Francois Xavier Gros, MD PhD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥18 years old
- Documented histological confirmation of aggressive B-cell non-Hodgkin lymphoma including DLBCL NOS and transformed indolent B-cell lymphoma
- Relapsed or refractory disease having received at least 2 prior lines of systemic treatment and, naïve to anti-CD3xCD20 bispecific antibody treatment (group 1) or exhausted all standard, available treatment options (group 2)
- At least 1 measurable site of disease based on computed tomography (CT) or positron emission tomography (PET)-CT scan with involvement of 2 or more clearly demarcated lesions and or nodes.
- Availability of lymph node tissue at Screening (or archival sample) (part 2 participants only)
- Life expectancy of ≥12 weeks.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
- Adequate organ function at Screening
- Adequate hematologic function
Exclusion Criteria:
-
Primary central nervous system (CNS) lymphoma or CNS involvement by lymphoma at screening.
-
Received anti-cancer treatments, including cytotoxic chemotherapy, radiotherapy, hormonal therapy, biologic, immunotherapy, or investigational drugs within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug. Prior treatment with CAR-T cell or an anti-CD3xCD20 bispecific antibody therapy (permitted for Group 2 only), requires a wash out period of ≥4 weeks.
-
Concurrent participation in another therapeutic clinical study.
-
Ongoing clinically significant toxicity (for example, alopecia is not clinically significant) from any prior anti-cancer therapy that has not resolved to Grade 1 or less prior to the first dose of study drug.
-
Prior treatment with a PIM inhibitor.
-
Group 1 only: Any prior therapy with a bispecific antibody targeting CD3 and CD20.
-
Known risk of allergy to the study drugs, MEN1703 (group 1 and 2) or glofitamab (group 1) or their excipients
-
Contraindication to all uric acid lowering agents.
-
Major surgery within 1 month prior to first dose of study drug.
-
Hematopoietic stem cell transplant within 4 months prior to first dose of study drug.
-
Requires systemic immune-modulating therapy (regardless of dose) or has confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression.
-
Exposed to live or live attenuated vaccine(s) within 4 weeks prior to signing the informed consent form (ICF).
-
Evidence of ongoing and uncontrolled systemic bacterial, fungal, or viral infection, except for documented Grade Common Terminology Criteria for Adverse Events (CTCAE) ≤2 infections with evidence of improvement or without evidence of worsening infection.
-
Known human immunodeficiency virus (HIV) infection
-
Current active liver disease from any cause
-
Ongoing drug-induced pneumonitis.
-
Ongoing inflammatory bowel disease.
-
Active known second malignancy
-
Received an agent known to be a sensitive CYP2D6 substrate or a CYP2D6 substrate with a narrow therapeutic range, a strong or moderate CYP2D6 inhibitor, or a BCRP inhibitor within 14 days or 5 half-lives (whichever is shorter), prior to the first dose of study drug.
-
Cardiac dysfunction is defined as myocardial infarction within 6 months of study entry, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled dysrhythmias, or poorly controlled angina.
-
Receiving treatment for active, ongoing thromboembolic event. Note: Does not apply to prophylactic treatment to prevent or avoid reoccurrence of a prior resolved event. To review with Medical Monitor where further risk assessment is needed.
-
History of serious ventricular arrhythmia (e.g., VT or VF, ≥3 beats in a row), or QT interval corrected for heart rate (QTc) ≥480 ms.
Note: QTc values up to 500 ms will be acceptable where patient's medical history e.g., bundle branch block, is known to cause mild QTc prolongation and the condition is well controlled.
-
Any disease, syndrome or condition which may significantly affect drug intake via oral route.
-
Planning to become pregnant or breastfeed during treatment and for 1 month after the last dose of study drug.
-
Any other prior or current medical condition, intercurrent illness, surgical history, physical or 12-lead electrocardiogram (ECG) findings, laboratory abnormalities, or extenuating circumstance (e.g., alcohol or drug addiction) that, in the investigator's opinion, could jeopardize patient safety or interfere with the objectives of the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: MEN1703 + glofitamab
• Participants who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will be given MEN1703 orally at a dose of 150 mg daily for 7 days or 125 mg daily for 14 days, in 21-day cycles for a maximum of 12 cycles, in combination with glofitamab administered as an IV infusion in a step-up dosing schedule starting with 2.5 mg on day 8 of cycle 1, and10 mg on day 15 of cycle 1, and 30 mg on day 1 from cycle 2 onward until disease progression or withdrawal, for a maximum of 12 cycles (parts 1, 2, 3)). All participants will be administered 1,000 mg of obinutuzumab as an IV infusion on cycle 1 day 1. • Participants who have exhausted all standard treatment options (group 2) will receive MEN1703 as a single-agent, at a dose of 125 mg orally every-day for 14 consecutive days in consecutive 21-day treatment cycles, until progressive disease (parts 1 and 2). |
MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
다른 이름들:
Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells. |
|
활성 비교기: Gofitamab
Participants who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will receive glofitamab as a single-agent administered as an IV infusion in a step-up dosing schedule starting with 2.5 mg on day 8 of cycle 1, and10 mg on day 15 of cycle 1, and 30 mg on day 1 from cycle 2 onward until disease progression or withdrawal, for a maximum of 12 cycles (part 3). |
Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Incidence and severity of adverse events (AE)
기간: 12 months
|
Assessed as the number and grade of adverse events assessed by CTCAE v5.0 |
12 months
|
|
Part 2 and Part 3: Complete response (CR) (group 1)
기간: 12 months
|
Assessed per Lugano Response Criteria for Malignant Lymphoma |
12 months
|
|
Part 2 and Part 3: Overall response rate (group 2)
기간: 12 months
|
Assessed as the number of patients who achieve a complete response (CR) or partial response (PR), per Lugano Response Criteria, divided by the total number of evaluable patients |
12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 2 and Part 3, Incidence and severity of AE
기간: 12 months
|
Assessed as the number and grade of adverse events assessed by CTCAE v5.0 |
12 months
|
|
Maximum Plasma Concentration (Cmax)
기간: 12 months
|
Assessment of the peak plasma concentration (Cmax) |
12 months
|
|
Maximum Plasma Concentration (Tmax)
기간: 12 months
|
Assessment of the time to peak plasma concentration (Tmax) |
12 months
|
|
Area Under the Concentration Time-Curve (AUC)
기간: 12 months
|
Assessed of the area under the plasma concentration versus time curve (AUC) |
12 months
|
|
Impact of treatment on patient reported outcomes (PRO)
기간: 12 months
|
Assessed as changes in lymphoma symptoms, well-being, and general health status measured according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) consisting of 30 questions that assess five domains of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), global health status/quality of life (GHS/QoL), and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All are scored from 0 to 100, with higher scores on the five domains and GHS/QoL being reflective of better health related (HR) QoL, and higher scores on the symptom scales and single items reflective of poor HRQoL. |
12 months
|
|
Impact of treatment on quality of life (QOL)
기간: 12 months
|
Assessed as changes in lymphoma symptoms and health related quality of life (HRQoL) as measured using the 15-item Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) including physical, social/family, emotional, and functional well-being and includes a lymphoma-specific subscale. The scale range is 0 to 60, with a higher score reflecting a better HRQoL. |
12 months
|
|
Overall survival (OS)
기간: 12 months
|
Assessed as the time from first treatment to death. |
12 months
|
|
Progression-free survival (PFS)
기간: 12 months
|
Assessed as time from the time from first treatment to the first occurrence of disease progression or death. |
12 months
|
|
Duration of Response (DoR)
기간: 12 months
|
Assessed as the time from first response (CR or PR) to the first occurrence of disease progression or death. |
12 months
|
|
Duration of Complete Response (DoCR)
기간: 12 months
|
Assessed as the time from first complete response (CR) to the first occurrence of disease progression or death. |
12 months
|
|
Time to response
기간: 12 months
|
Assessed as the time from the first treatment to the time of first response (CR or PR). |
12 months
|
|
Time to next treatment
기간: 12 months
|
Assessed as the time from the first treatment to the start date of the first therapy received after the participant has ended study treatment and received subsequent anti-lymphoma therapy. |
12 months
|
공동 작업자 및 조사자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- JASPIS-01
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .